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Abstracts 
NTOX-04. INVESTIGATION OF N-ACETYLCYSTEINE FOR THE 
PREVENTION OF CISPLATIN CHEMOTHERAPY-RELATED 
COGNITIVE IMPAIRMENTS 
Naomi Lomeli, Kaijun Di, Jennifer Czerniawski, John F. Guzowski and 
Daniela A. Bota; University of California, Irvine, Irvine, CA, USA 
OBJECTIVES: Chemotherapy-related cognitive impairment (CRCI) is a 
major clinical problem, which diminishes the quality of life of cancer sur-
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vivors. We focus on the neurocognitive impairments provoked by cisplatin, 
a chemotherapy agent widely used as treatment for various malignancies 
including ovarian, testicular, head and neck cancers, and pediatric brain 
tumors. More than 30% of advanced ovarian cancer patients develop CRCI 
during and after cisplatin-based chemotherapy. We examined mitochondrial 
dysfunction as a mechanism underlying cisplatin CRCI, and the ability of the 
antioxidant N-acetylcysteine to mitigate these toxicities in a rat model, and 
in-vitro in cultured rat hippocampal neurons and neural stem/progenitor 
cells (NSC). METHODS: We examined the effects of cisplatin on neuronal 
morphology, apoptosis, and cognition in rats. We assessed the effects of cis­
platin on mitochondrial respiratory function, reactive-oxygen species (ROS) 
production, caspase-9 activation, and glutathione levels in-vitro. RESULTS:
Cisplatin reduced neuronal dendritic branching and spine density and 
induced apoptotic cell death in the rat hippocampus. Chronic cisplatin 
treatment impaired cognitive function; this impairment was mitigated by 
N-acetylcysteine administration. In-vitro, cisplatin damaged mitochondrial 
DNA, impaired respiratory activity, elevated ROS levels, and depleted glu­
tathione. N-acetylcysteine mitigated cisplatin-induced neural ROS levels and 
glutathione depletion, apoptotic cell death, and neuronal post-synaptic den­
sity-95 puncta loss, while not interfering with cisplatin's anti-cancer effect 
in two ovarian cancer cell lines when administered 10 h following cisplatin. 
DISCUSSION: The cognitive deficits caused by cisplatin in rats result from 
the loss of excitatory synapses and dendritic spines that anchor them, as well 
as from injury to mature and developing neurons. This neuronal toxicity 
derives from mitochondrial damage. Importantly, treatment with N-acetyl­
cysteine mitigates cisplatin-induced neurotoxicity and cognitive deficits. We 
are planning a Phase I study to examine if NAC administration to ovarian 
cancer patients receiving cisplatin is safe, and if it ameliorates the cognitive 
deficits previously described in this patient population. 
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